ALKERMES reported $631.31M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
AbbVie USD 10.77B 4.2B Sep/2026
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
ALKERMES USD 631.31M 119.78M Sep/2026
Amgen USD 13.19B 799M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
Heron Therapeutics USD 11.6M 9.13M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Malin Corporation EUR 62.1M 26.4M Dec/2024
Merck USD 9.55B 2.7B Sep/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Otsuka Holdings JPY 472.49B 2.94B Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026